MYOHealthcare · Medical DevicesThe 5 Wall Street analysts covering Myomo, Inc. hold a median 12-month price target of $3 — +130.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 28 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Myomo, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (88): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (10): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MYO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +130.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Aug 2026 | Ascendiant Capital | Maintains | Buy | — |
| 8 June 2026 | Ascendiant Capital | Maintains | Buy | — |
| 21 Nov 2025 | Ascendiant Capital | Maintains | Buy | — |
| 22 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 12 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 June 2025 | Craig-Hallum | Maintains | Buy | — |
| 5 June 2025 | Ascendiant Capital | Maintains | Buy | — |
| 8 May 2025 | Craig-Hallum | Maintains | Buy | — |
| 17 Mar 2025 | Ascendiant Capital | Maintains | Buy | — |
| 12 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Mar 2025 | Craig-Hallum | Maintains | Buy | — |
| 13 Dec 2024 | Craig-Hallum | Maintains | Buy | — |
| 13 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | $7.50 |
| 12 Nov 2024 | Ascendiant Capital | Maintains | Buy | — |
| 19 Aug 2024 | Ascendiant Capital | Maintains | Buy | — |
| 12 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 July 2024 | Craig-Hallum | Initiates | Buy | — |
| 9 July 2024 | Lake Street | Maintains | Buy | — |
| 9 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Dec 2023 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MYO appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Myomo, Inc. returned +34.7% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 65% of US stocks
Cheaper than 10% of US stocks
Cheaper than 81% of US stocks
Higher than 70% of US stocks
Higher than 60% of US stocks
Higher than 84% of US stocks
Higher than 21% of US stocks
Higher than 13% of US stocks
Higher than 11% of US stocks
Higher than 19% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Myomo, Inc. has a market value of $49.9M and an enterprise value of $56.5M.
Revenue in the twelve months to 30 June 2026: $43.3M. The latest quarter grew 21.3% year on year.
Net income over the same four quarters: −$14.5M, a −33.5% net margin.
Diluted earnings per share, trailing twelve months: $−0.34.
Free cash flow in the twelve months to 30 June 2026: −$9.1M.
Trailing P/E: −3.4×; forward P/E: −5.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Myomo, Inc. employs 194 people — $223K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Myomo, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Myomo appointed Mary-Katherine “Katie” McClure as Chief Commercial Officer, effective October 12, 2026. She will succeed Micah Mitchell, who is departing after a leadership transition period.
Why it matters — The appointment marks a change in Myomo’s commercial leadership.
Myomo, Inc. announced it will participate in the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14-16, 2026 at the Lotte Palace Hotel in New York. The company's President and CEO Paul Gudonis and CFO are scheduled to attend.
Why it matters — The company's attendance at a major investment conference provides an opportunity for management to present to investors and the financial community, which MYO watchers would follow.
Myomo reported 21% revenue growth for the second quarter of 2026. The wearable robotics company continued shifting its patient acquisition strategy toward recurring referral sources and expanded reimbursement relationships, as highlighted in its earnings call.
Why it matters — A Myomo watcher would care because continued revenue growth and a stronger recurring referral and reimbursement model signal improving commercial traction for its wearable robotics business.
Seeking Alpha published the transcript of Myomo, Inc.'s Q2 2026 earnings call, providing the company's discussion of its quarterly results. The item signals that the earnings call transcript is now available to investors.
Why it matters — A MYO watcher would look to this transcript for management's firsthand commentary on the company's second-quarter performance and outlook.
Myomo, Inc. reported a second-quarter loss of $0.07 per share, which was narrower than the Zacks Consensus Estimate of a $0.10 loss and better than the $0.11 loss a year earlier. The company also topped revenue estimates for the quarter.
Why it matters — MYO watchers would care because the results came in better than consensus expectations on both the loss and revenue side, signaling improved performance relative to forecasts.
The 5 Wall Street analysts covering Myomo, Inc. have a median 12-month price target of $3, with estimates ranging from $1.7 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Myomo, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Myomo, Inc. 64 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Myomo, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (88 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +130.8% from the last close, and Ticker Nerd's factor model ranks Myomo, Inc. 64 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Myomo, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MYO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.7 to $11 over the next 12 months.
Myomo, Inc. returned +34.7% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Myomo Inc. is a medical robotics company that develops and markets myoelectric orthotic devices for people with neuromuscular disorders and upper-limb paralysis.
The most recent item we track (Business Wire, 12 Oct 2026): "Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer". Myomo appointed Mary-Katherine “Katie” McClure as Chief Commercial Officer, effective October 12, 2026. She will succeed Micah Mitchell, who is departing after a leadership transition period.
Myomo Inc. is a medical robotics company that develops and markets myoelectric orthotic devices for people with neuromuscular disorders and upper-limb paralysis. Its flagship MyoPro product line is a powered arm brace designed to support weakened or paralyzed arms and hands by detecting the user’s own muscle signals through non-invasive sensors. The company serves patients recovering from or living with conditions such as stroke, spinal cord injury, brachial plexus injury, traumatic brain injury, ALS, and multiple sclerosis. Myomo Inc. sells its devices through orthotics and prosthetics providers, direct clinical and insurance-based channels, the Veterans Administration, and selected distributors in the United States and international markets. The company focuses on restoring upper-limb function, supporting daily activities, and improving mobility for individuals with neurological and muscular impairments.
CEO Mr. Paul R. Gudonis · 194 employees · United States · https://myomo.com
